These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 21333823

  • 1. [Squamous cell carcinoma in a patient receiving sorafenib].
    Adnot-Desanlis L, Bernard P, Reguiaï Z.
    Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
    [Abstract] [Full Text] [Related]

  • 2. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R.
    Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
    [Abstract] [Full Text] [Related]

  • 3. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Smith KJ, Haley H, Hamza S, Skelton HG.
    Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
    [Abstract] [Full Text] [Related]

  • 4. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ, Kish LS, Jaworsky C.
    J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
    Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM.
    Clin Genitourin Cancer; 2009 Jan; 7(1):20-3. PubMed ID: 19213663
    [Abstract] [Full Text] [Related]

  • 6. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR, Stetson CL, Smith JL.
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract] [Full Text] [Related]

  • 7. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
    El Tal AK, Remichofsky CJ, Mehregan DA, Ganger LK.
    Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
    [No Abstract] [Full Text] [Related]

  • 8. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
    Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC, Mateus C, Robert C.
    J Clin Oncol; 2009 Aug 10; 27(23):e59-61. PubMed ID: 19597016
    [No Abstract] [Full Text] [Related]

  • 9. [Sorafenib-induced multiple eruptive keratoacanthomas].
    Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J.
    Ann Dermatol Venereol; 2009 Dec 10; 136(12):894-7. PubMed ID: 20004316
    [Abstract] [Full Text] [Related]

  • 10. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
    Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.
    J Clin Oncol; 2012 Jan 20; 30(3):316-21. PubMed ID: 22067401
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib.
    Hasskarl J.
    Recent Results Cancer Res; 2010 Jan 20; 184():61-70. PubMed ID: 20072831
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.
    Arch Dermatol; 2008 Jun 20; 144(6):820-2. PubMed ID: 18559790
    [No Abstract] [Full Text] [Related]

  • 13. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
    Lynch MC, Straub R, Adams DR.
    J Drugs Dermatol; 2011 Mar 20; 10(3):308-10. PubMed ID: 21369650
    [Abstract] [Full Text] [Related]

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 20; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group.
    N Engl J Med; 2007 Jan 11; 356(2):125-34. PubMed ID: 17215530
    [Abstract] [Full Text] [Related]

  • 16. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW.
    Dermatol Surg; 2013 Jul 11; 39(7):981-7. PubMed ID: 23464361
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
    Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R.
    Dermatology; 2010 Jul 11; 221(3):193-6. PubMed ID: 20720388
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.